Flag of the European Union EU Clinical Trials Register Help

Clinical trials for docetaxel

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    762 result(s) found for: docetaxel. Displaying page 1 of 39.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-003785-77 Sponsor Protocol Number: 59244 Start Date*: 2017-03-16
    Sponsor Name:
    Full Title: Microdosing as a tool to individualize docetaxel dosing: development of a limited sampling model
    Medical condition: Patients with breast-, prostate or non-small cell lung cancer (NSCLC), who are eligible for treatment with docetaxel.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003228-39 Sponsor Protocol Number: D4320C00033 Start Date*: 2008-02-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metasta...
    Medical condition: hormone-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) NL (Completed) GB (Prematurely Ended) FR (Completed) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) PT (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001269-10 Sponsor Protocol Number: Doc-Pred Start Date*: 2016-07-14
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: A pharmacokinetic study of Docetaxel and Prednisone in men with metastatic castration-resistant or hormone-sensitive prostate cancer.
    Medical condition: Metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003622-25 Sponsor Protocol Number: D1532C00064 Start Date*: 2012-12-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, Compared with Pla...
    Medical condition: Locally Advanced or Metastatic Non Small Cell Lung Cancer stage IIIb - IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) NL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-005174-68 Sponsor Protocol Number: UZL OFT-AMO 001 Start Date*: 2006-04-21
    Sponsor Name:UZLeuven Afdeling Oogziekten
    Full Title: A Double blind Interventional study exploring the efficacy of topical eye treatment in the prevention of Docetaxel induced Dacryostenosis.
    Medical condition: The rationale of this randomized double blind study is to investigate the efficacy of topical eye treatment in patients on a weekly Docetaxel regimen in prevention of dacryostenosis. The dacryotoxi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003433-37 Sponsor Protocol Number: 213410 Start Date*: 2021-03-10
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A RANDOMIZED, OPEN-LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WHO HAV...
    Medical condition: Nonsmall Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004034-38 Sponsor Protocol Number: MK-7684A-002 Start Date*: 2021-04-19
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-...
    Medical condition: Non Small Cell Lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002480-26 Sponsor Protocol Number: CACZ885V2301 Start Date*: 2018-12-03
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subje...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) DE (Completed) FR (Completed) ES (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) HU (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002625-77 Sponsor Protocol Number: DCT1 Start Date*: 2007-07-03
    Sponsor Name:FONDAZIONE ISTITUTO SAN RAFFAELE-G.GIGLIO
    Full Title: Randomized phase II trial of first line chemoterapy Docetaxel given in combination with Cisplatin for 6 cycles or Docetaxel given in combination with Cisplatin for 3 cycles followed by Docetaxel al...
    Medical condition: Patients with advanced non-small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026532 Malignant neoplasm of thorax LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005060-15 Sponsor Protocol Number: EMR100070-004 Start Date*: 2015-06-23
    Sponsor Name:Merck KGaA
    Full Title: A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Prematurely Ended) GB (Completed) BE (Completed) HU (Completed) DK (Completed) AT (Completed) ES (Completed) NL (Completed) FR (Completed) CZ (Completed) PL (Completed) HR (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2013-001676-38 Sponsor Protocol Number: D1532C00079 Start Date*: 2013-09-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients rece...
    Medical condition: Locally Advanced or Metastatic Non Small Cell Lung Cancer stage IIIb - IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) IT (Completed) DE (Completed) NL (Ongoing) AT (Completed) ES (Temporarily Halted) BE (Completed) SE (Completed) PL (Completed) PT (Completed) FR (Ongoing) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018153-23 Sponsor Protocol Number: Start Date*: 2010-09-30
    Sponsor Name:University of Oxford
    Full Title: A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma
    Medical condition: Advanced metastatic melanoma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024164-18 Sponsor Protocol Number: 1200.138 Start Date*: 2011-06-20
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Single-arm, open-label, monocentric Phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) for the treatment of patients with HER2-positive, hormone-refractory prostate cancer af...
    Medical condition: Patients with HER2-positive, hormone-refractory prostate cancer after failure of treatment with docetaxel or ineligible for treatment with docetaxel.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003791-12 Sponsor Protocol Number: MK-7902-008 Start Date*: 2019-03-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously trea...
    Medical condition: NSCLC with squamous or nonsquamous histology
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2022-003792-41 Sponsor Protocol Number: DAROTAXEL Start Date*: 2023-05-26
    Sponsor Name:Erasmus MC
    Full Title: A randomized phase II trial of docetaxel or cabazitaxel with or without darolutamide in men with metastatic castration-resistant prostate cancer.
    Medical condition: metastatic castration-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002943-28 Sponsor Protocol Number: 1839IL/0721 Start Date*: 2004-11-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Open Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastat...
    Medical condition: Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004243-23 Sponsor Protocol Number: J1S-MS-JV02 Start Date*: 2021-05-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with relapsed, Recurrent, or Refractory Synovial Sarcoma.
    Medical condition: Synovial Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002605-10 Sponsor Protocol Number: CJDQ443B12301 Start Date*: 2022-04-01
    Sponsor Name:Novartis Pharma AG
    Full Title: KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic K...
    Medical condition: Advanced non-small cell lung cancer harboring the KRAS G12C mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Trial now transitioned) ES (Ongoing) NO (Completed) GR (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) DK (Completed) SI (Trial now transitioned) EE (Completed) IT (Trial now transitioned) PL (Completed) HR (Completed) IS (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001965-98 Sponsor Protocol Number: PGFN-001 Start Date*: 2017-01-10
    Sponsor Name:Prolong Pharmaceuticals, LLC
    Full Title: A randomized and open-label dose-finding, phase 2, efficacy, safety, and pharmacokinetic study of once-per-cycle prophylactic injections of ANF-RHO™ versus pegfilgrastim (Neulasta®) in non-metastat...
    Medical condition: chemotherapy-induced neutropenia (CIN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10076734 Chemotherapy induced neutropenia LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014491-21 Sponsor Protocol Number: Start Date*: 2009-12-17
    Sponsor Name:Cambridge University Hospitals NHS Trust
    Full Title: Neoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy.
    Medical condition: Neoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 07:43:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA